Creative Biogene provides kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. Creative Biogene holds a leadership position in the global market and is committed to improving the human condition through biotechnology.
Creative Biogene is a US-based manufacturer and provider of genomics and proteomics products and services for academic and governmental research institutes, pharmaceutical and biotechnology industry.
Contact
Wendy Wilson
Tel: 1-516-669-8109
Email: contact@creative-
Address: 45-1 Ramsey Road, Shirley, NY 11967, USA
Website: www.creative-biogene.
Falling prices are squeezing US generic and biosimilar manufacturers too hard, argues John Murphy III, President and CEO of the Association for Accessible Medicines (AAM). Generic prices have dropped an…
Thomas Seewoester, Vice President Site Operations and Site Head at Amgen Manufacturing Limited, LLC, has overseen Puerto Rico’s most significant manufacturing campus for three years, building on more than three…
Innovators should hold CDMOs to a high bar, and CDMOs need to step up Syed T. Husain, Chairman & CEO of Made Scientific, outlines the organization’s differentiated strategy to disrupt…
The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for…
Innovation cannot stop at the laboratory door. It must extend to how therapies are developed, approved, and reimbursed Brian Campbell, Vice President and General Manager of the US for Orchard…
Joshua Salsi, Head of North America, Biocon Biologics explains the company’s evolution into an integrated, global biosimilars company following the 2022 Viatris portfolio reacquisition. He highlights the company’s growing US…
Pamela Gavin, CEO of the National Organization for Rare Disorders, discusses NORD’s origins in the advocacy movement that led to the Orphan Drug Act and its current mission to improve…
Daniel Camardo is the President of Immedica Pharma US Inc. (Immedica), the US affiliate/subsidiary of Immedica Pharma AB, a Sweden-based rare disease company that entered the American market in 2024.…
Gilmore O’Neill, CEO of Editas Medicine, reflects on the company’s evolution from CRISPR pioneer to focused in vivo therapeutics developer. Two years into a strategic pivot, O’Neill shares the reasoning…
Randy Pritchard, General Manager and Senior Vice President of Clinical Operations for North America at bioMérieux, a global leader in in vitro diagnostics, speaks about the outsized strategic weight of…
Leonard Paolillo, President of Merz Therapeutics North America, shares what it means to be a growing player in the specialty neurology space. Two years after the company’s acquisition of INBRIJA®…
Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this…
See our Cookie Privacy Policy Here
